Comparing neoadjuvant radiochemotherapy protocols for resectable esophageal cancer, this study finds no significant differences in postoperative mortality, complications, or toxicity. Both PF-based and CROSS protocols demonstrate effectiveness and safety, with squamous cell carcinoma and favorable tumor grading independently predicting a higher pathological complete response rate. The battle of protocols concludes with similar outcomes, providing valuable insights for treatment decisions in locally advanced esophageal cancer.
Journal Article by Lorenz E, Weitz A (…) Benedix F et 3 al. in Langenbecks Arch Surg
© 2023. The Author(s).